GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
376
Phillips Edison & Co
PECO
$4.54B
| $84.7K | ﹤0.01% |
2,322
+96
| +4% | +$3.5K |
|
|
SWTX
377
DELISTED
SpringWorks Therapeutics
SWTX
| $84.1K | ﹤0.01% |
1,905
+343
| +22% | +$15.1K |
|
378
Rhythm Pharmaceuticals
RYTM
$6.78B
| $83.3K | ﹤0.01% |
1,573
+283
| +22% | +$15K |
|
379
Macerich
MAC
$4.74B
| $80.8K | ﹤0.01% |
4,707
+191
| +4% | +$3.28K |
|
380
Crinetics Pharmaceuticals
CRNX
$3.35B
| $79.7K | ﹤0.01% |
2,375
+428
| +22% | +$14.4K |
|
381
SL Green Realty
SLG
$4.4B
| $78.4K | ﹤0.01% |
1,359
+181
| +15% | +$10.4K |
|
382
Sabra Healthcare REIT
SBRA
$4.56B
| $78.3K | ﹤0.01% |
4,481
+224
| +5% | +$3.91K |
|
383
Scholar Rock
SRRK
$3.02B
| $77K | ﹤0.01% |
2,396
+430
| +22% | +$13.8K |
|
384
EPR Properties
EPR
$4.05B
| $75.4K | ﹤0.01% |
1,434
+58
| +4% | +$3.05K |
|
385
CRISPR Therapeutics
CRSP
$4.99B
| $74.4K | ﹤0.01% |
2,186
+394
| +22% | +$13.4K |
|
386
Protagonist Therapeutics
PTGX
$3.77B
| $73.8K | ﹤0.01% |
1,526
+275
| +22% | +$13.3K |
|
387
Merus
MRUS
$5.1B
| $73.8K | ﹤0.01% |
1,753
+315
| +22% | +$13.3K |
|
388
Akero Therapeutics
AKRO
$3.58B
| $72.3K | ﹤0.01% |
1,787
+321
| +22% | +$13K |
|
389
Legend Biotech
LEGN
$6.66B
| $71K | ﹤0.01% |
2,092
+377
| +22% | +$12.8K |
|
390
Tanger
SKT
$3.94B
| $70.9K | ﹤0.01% |
2,097
+110
| +6% | +$3.72K |
|
391
Acadia Pharmaceuticals
ACAD
$4.26B
| $70.8K | ﹤0.01% |
4,260
+766
| +22% | +$12.7K |
|
392
Sweetgreen
SG
$1.06B
| $70.7K | ﹤0.01% |
+2,824
| New | +$70.7K |
|
393
Apellis Pharmaceuticals
APLS
$3.55B
| $69.7K | ﹤0.01% |
3,185
+573
| +22% | +$12.5K |
|
394
Kilroy Realty
KRC
$5.05B
| $69.6K | ﹤0.01% |
2,124
+98
| +5% | +$3.21K |
|
395
Amneal Pharmaceuticals
AMRX
$3.02B
| $66.5K | ﹤0.01% |
7,934
+1,428
| +22% | +$12K |
|
396
Alvotech
ALVO
$2.6B
| $66.1K | ﹤0.01% |
6,832
+1,229
| +22% | +$11.9K |
|
397
Xenon Pharmaceuticals
XENE
$3.02B
| $65.5K | ﹤0.01% |
1,952
+351
| +22% | +$11.8K |
|
398
Immunovant
IMVT
$2.99B
| $64.2K | ﹤0.01% |
3,758
+676
| +22% | +$11.6K |
|
399
National Health Investors
NHI
$3.72B
| $63.5K | ﹤0.01% |
860
+20
| +2% | +$1.48K |
|
400
Amicus Therapeutics
FOLD
$2.46B
| $62.4K | ﹤0.01% |
7,651
+1,377
| +22% | +$11.2K |
|